查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
片段抗体市场规模、份额和趋势分析报告：特异性（单克隆抗体、多克隆抗体）、类型、治疗、应用、地区、分部预测，2022-2030
市场调查报告书
商品编码
1122223

片段抗体市场规模、份额和趋势分析报告：特异性（单克隆抗体、多克隆抗体）、类型、治疗、应用、地区、分部预测，2022-2030

Antibody Fragments Market Size, Share & Trends Analysis Report By Specificity (Monoclonal Antibodies, Polyclonal Antibodies), By Type, By Therapy, By Application, By Region, And Segment Forecasts, 2022 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

片段抗体市场增长及趋势

根据 Grand View Research, Inc. 的一份新报告，到 2030 年，全球片段抗体市场规模预计将达到 113.6 亿美元，从 2022 年到 2030 年，复合年增长率为 5.9%。由于人口老龄化和社会行为的变化，慢性病在全球范围内稳步增加。城市化进程的加快导致中产阶级不断壮大，人们过着更久坐和不健康的生活方式，从而导致糖尿病等疾病的增加。由于人口显着增长，预计新兴市场将承受最大的患者负担。

此外，主要市场参与者的投资增加有助于行业的增长。例如，2020 年 6 月，范德比尔特大学医学中心与阿斯利康合作，将该公司的冠状病毒中和抗体推进临床开发，作为治疗和预防 COVID-19 的可能联合疗法。预计这些因素将在未来几年推动市场。

抗体是检测分子和蛋白质的重要工具。儘管对于大多数免疫分析应用来说，全抗体是首选，但一些实验仅受益于抗体片段，例如 F(ab')2 和 Fab。单克隆抗体是一类重要的被批准用于治疗各种癌症的治疗剂。超过 80 种抗体已被批准用于各种疾病适应症，使这些抗体成为最大的生物製药类别。更小、更多抗原结合抗体片段的引入正在快速增长，并对行业产生积极影响。

由于较低的製造和纯化成本，预计片段抗体也将优于全链抗体。使用片段抗体治疗某些疾病可能会受到严格的 ICD-10 法规的限制。然而，针对严重疾病的片段抗体临床开发的新进展可能会提供重要的市场增长机会。

片段抗体市场报告亮点

根据特异性，单克隆抗体在 2021 年占最大份额，因为它们被认为是推荐用于治疗多种形式恶性肿瘤的重要治疗药物类别。

按类型划分，scFv 细分市场预计将在未来几年见证最快的增长。scFv 与它们的亲本 mAb 相比具有几个优点，包括多价性、异质性生产力、低分子量和多聚体。

通过治疗，单克隆抗体细分市场将在 2021 年引领市场。雷珠单抗（Lucentis）将在 2021 年拥有最大的收入份额，因为它用于治疗糖尿病性黄斑水肿、新生血管（湿性）年龄相关性黄斑变性（AMD）等引起的视力障碍。

通过应用，由于随着全球癌症患病率的上升，越来越多地采用片段抗体用于治疗目的，预计肿瘤学领域将在预测期内增长最快。

2021 年，北美主导市场，由于免疫缺陷疾病的增加，对用于研究目的的片段抗体的需求不断增加。

由于私人和公共合作伙伴对生物技术和药物研究的投资增加，预计亚太地区未来将显着增长。这刺激了片段抗体的采用。

目录

第一章执行摘要

  • 市场快照
  • 竞争环境
  • 分部展望

第二章研究方法论

  • 信息采购
  • 信息或数据分析
  • 市场製定和验证

3. 片段抗体市场变量、趋势和范围

  • 母市场分析
  • 市场动态
    • 市场驱动力分析
      • 感染和慢性病的患病率增加
      • 片段抗体优于其他选择
      • 增加对製药和生物技术研究的公共和私人投资
    • 市场约束分析
      • 片段抗体纯化的障碍

4 片段抗体市场：细分分析，按特异性，2018-2030 年（百万美元）

  • 定义和范围
  • 全球片段抗体市场，按特异性，2018-2030 年（百万美元）
  • 市场规模和预测、趋势分析，2018 年至 2030 年，百万美元
    • 单克隆抗体
    • 多克隆抗体

5. 片段抗体市场：细分分析，按类型，2018-2030 年（百万美元）

  • 定义和范围
  • 2018-2030 年按类型分列的全球片段抗体市场（百万美元）
  • 市场规模和预测，趋势分析，2018-2030
    • 惊人
    • 单链抗体
    • 抗体
    • 其他

6. 片段抗体市场：细分分析，按疗法，2018-2030 年（百万美元）

  • 定义和范围
  • 全球片段抗体市场，按疗法，2018-2030 年（百万美元）
  • 2018-2030 年市场规模和预测、趋势分析（百万美元）
    • Monoclonal Antibodies
    • Praxbind (idarucizumab)
    • Ranibizumab (Lucentis)
    • Certolizumab pegol (Cimzia)
    • Iodine (1311) Metuximab/Licartin
    • Beovu (brolucizumab-dbl)
    • Cablivi (caplacizumab-yhdp)
    • blinatumomab/brinsite
    • PAB
    • CroFab
    • Anavip
    • Anascope
    • Botulism Antitoxin Heptavalent (HBAT)
    • Digibind
    • DigiFab
    • Pipeline
    • AFM13
    • HPN-424
    • MGD007
    • Tebotelimab (MGD013)
    • Bentracimab (PB2452)
    • Flotetuzumab (MGD006)
    • AK104
    • Ozoralizumab
    • Sonelokimab (ALX0761)

7. 片段抗体市场：细分分析，按应用，2018-2030 年（百万美元）

  • 定义和范围
  • 2018-2030年按应用分列的全球片段抗体市场（百万美元）
  • 2018-2030 年市场规模和预测、趋势分析（百万美元）
    • 癌症
    • 免疫缺陷
    • 其他

8. 片段抗体市场：区域市场分析，2018-2030（百万美元）

  • 定义和范围
  • 2021 年和 2030 年区域市场份额分析
  • 区域市场仪表板
  • 区域市场：主要参与者
  • 2018-2030 年市场规模、预测和趋势分析
  • 北美
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 俄罗斯
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳大利亚
    • 韩国
    • 新加坡
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙特阿拉伯
    • 阿拉伯联合酋长国

第 9 章 竞争格局

  • 战略框架
  • 市场参与的分类
  • 公司简介
    • Pfizer Inc
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • Sanofi
      • 公司简介
      • Albynx
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • Novartis AG
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • Genentech, Inc.
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • AbbVie Inc.
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • Bristol-Myers Squibb Company
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • Johnson & Johnson Services, Inc.
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • Lilly
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
Product Code: GVR-4-68039-973-2

Antibody Fragments Market Growth & Trends:

The global antibody fragments market size is expected to reach USD 11.36 billion by 2030, according to a new report by Grand View Research, Inc., expanding at a CAGR of 5.9% from 2022 to 2030. There has been a steady increase in chronic conditions across the globe owing to the increasing geriatric population and societal behavior changes. The expediting urbanization is leading to the growth of the middle class resulting in people adopting a more sedentary and unhealthier lifestyle, in turn, causing an increase in diseases such as diabetes. The emerging markets are predicted to hold the largest patient burden owing to the significant population growth.

Furthermore, growing investments by the key market players have contributed to the industry growth. For instance, in June 2020, Vanderbilt University Medical Center collaborated with AstraZeneca to advance the company's coronavirus-neutralizing antibodies into clinical development as a possible combination therapy for the treatment and prevention of COVID-19. These factors would drive the market in the coming years.

Antibodies are an important tool for molecular and protein detection. Even though whole antibodies are preferable for most immunoassay applications, the performance for some experiments is only enhanced by antibody fragments, such as F(ab')2 and Fab. Monoclonal antibodies are a significant class of therapeutic drugs that have received approval to treat various cancers. With more than 80 antibodies already approved for use in various disease indications, these antibodies represent the largest class of biopharmaceuticals. The introduction of smaller, antigen-binding antibody fragments has been growing at a fast pace, which is impacting the industry positively.

Antibody fragments are also anticipated to be preferred over full-chain antibodies due to their lower manufacturing and purification costs. The use of antibody fragments for the treatment of a specific disease may be constrained by strict ICD-10 rules. However, the new advancements in the clinical development of antibody fragments for serious diseases may offer significant market growth opportunities.

Antibody Fragments Market Report Highlights:

  • By specificity, monoclonal antibodies held the largest share in 2021 as they are considered a significant class of therapeutic agents recommended in the therapy of several forms of malignancies
  • Based on type, the scFv segment is anticipated to witness the fastest growth in the coming years. They provide several advantages such as multivalency, heterologous production, low molecular weight, and multimeric form over the parent mAb
  • By therapy, the monoclonal antibodies segment led the market in 2021. Ranibizumab (Lucentis) captured the largest revenue share in 2021 as these are used for the treatment of visual impairment due to diabetic macular edema, neovascular (wet) age-related macular degeneration (AMD), and others
  • By application, the cancer segment is expected to witness the fastest growth over the forecast period owing to the increasing prevalence of cancer globally, which is resulting in the increasing adoption of antibody fragments for therapeutic purposes
  • North America dominated the market in 2021 owing to the increasing prevalence of immunodeficiency diseases, which has led to the increasing demand for antibody fragments for research purposes
  • Asia Pacific is expected to grow considerably in the future owing to increasing private and public partnership investments in biotech and pharmaceutical research. This has fueled the adoption of antibody fragments

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Competition Milieu
  • 1.3. Segment Outlook

Chapter 2. Research Methodology

  • 2.1. Information Procurement
  • 2.2. Information or Data Analysis
  • 2.3. Market Formulation & Validation

Chapter 3. Antibody Fragments Market Variables, Trends & Scope

  • 3.1. Parent Market Analysis
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of infectious and chronic diseases
      • 3.2.1.2. Antibody fragments are preferred over other alternatives
      • 3.2.1.3. Increasing public-private investments for pharma and biotech research
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Obstacles in the purification of antibody fragments

Chapter 4. Antibody Fragments Market: Segment Analysis, By Specificity, 2018 - 2030 (USD Million)

  • 4.1. Definitions & Scope
  • 4.2. Global Antibody Fragments Market, By Specificity, 2018 to 2030 (USD Million)
  • 4.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 USD Million
    • 4.3.1. Monoclonal Antibodies
      • 4.3.1.1. Global Antibody Fragments Market, Monoclonal Antibodies, 2018 to 2030 (USD Million)
    • 4.3.2. Polyclonal Antibodies
      • 4.3.2.1. Global Antibody Fragments Market, Monoclonal Antibodies, 2018 to 2030 (USD Million)

Chapter 5. Antibody Fragments Market: Segment Analysis, By Type, 2018 - 2030 (USD Million)

  • 5.1. Definitions & Scope
  • 5.2. Global Antibody Fragments Market, By Type, 2018 to 2030 (USD Million)
  • 5.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030
    • 5.3.1. FAB
      • 5.3.1.1. Global Antibody Fragments Market, FAB, 2018 to 2030 (USD Million)
    • 5.3.2. scFv
      • 5.3.2.1. Global Antibody Fragments Market,scFv, 2018 to 2030 (USD Million)
    • 5.3.3. sdAb
      • 5.3.3.1. Global Antibody Fragments Market, sdAb, 2018 to 2030 (USD Million)
    • 5.3.4. Others
      • 5.3.4.1. Global Antibody Fragments Market, others, 2018 to 2030 (USD Million)

Chapter 6. Antibody Fragments Market: Segment Analysis, By Therapy, 2018 - 2030 (USD Million)

  • 6.1. Definitions & Scope
  • 6.2. Global Antibody Fragments Market, By Therapy, 2018 to 2030 (USD Million)
  • 6.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
    • 6.3.1. Monoclonal Antibodies
    • 6.3.2. Praxbind (idarucizumab)
      • 6.3.2.1. Global Antibody Fragments Market, Praxbind (idarucizumab), 2018 to 2030 (USD Million)
    • 6.3.3. Ranibizumab (Lucentis)
      • 6.3.3.1. Global Antibody Fragments Market, Ranibizumab (Lucentis), 2018 to 2030 (USD Million)
    • 6.3.4. Certolizumab pegol (Cimzia)
      • 6.3.4.1. Global Antibody Fragments Market, Certolizumab pegol (Cimzia), 2018 to 2030 (USD Million)
    • 6.3.5. Iodine (1311) Metuximab/ Licartin
      • 6.3.5.1. Global Antibody Fragments Market, Iodine (1311) Metuximab/ Licartin, 2018 to 2030 (USD Million)
    • 6.3.6. Beovu (brolucizumab-dbll)
      • 6.3.6.1. Global Antibody Fragments Market, Beovu (brolucizumab-dbll), 2018 to 2030 (USD Million)
    • 6.3.7. Cablivi (caplacizumab-yhdp)
      • 6.3.7.1. Global Antibody Fragments Market, Cablivi (caplacizumab-yhdp), 2018 to 2030 (USD Million)
    • 6.3.8. Blinatumomab/ Blincyto
      • 6.3.8.1. Global Antibody Fragments Market, Blinatumomab/ Blincyto, 2018 to 2030 (USD Million)
    • 6.3.9. PAB
    • 6.3.10. CroFab
      • 6.3.10.1. Global Antibody Fragments Market, CroFab, 2018 to 2030 (USD Million)
    • 6.3.11. Anavip
      • 6.3.11.1. Global Antibody Fragments Market, Anavip, 2018 to 2030 (USD Million)
    • 6.3.12. Anascorp
      • 6.3.12.1. Global Antibody Fragments Market, Anascorp, 2018 to 2030 (USD Million)
    • 6.3.13. Botulism Antitoxin Heptavalent (HBAT)
      • 6.3.13.1. Global Antibody Fragments Market, Botulism Antitoxin Heptavalent (HBAT), 2018 to 2030 (USD Million)
    • 6.3.14. Digibind
      • 6.3.14.1. Global Antibody Fragments Market, Digibind, 2018 to 2030 (USD Million)
    • 6.3.15. DigiFab
      • 6.3.15.1. Global Antibody Fragments Market, DigiFab, 2018 to 2030 (USD Million)
    • 6.3.16. Pipeline
    • 6.3.17. AFM13
      • 6.3.17.1. Global Antibody Fragments Market, AFM13, 2018 to 2030 (USD Million)
    • 6.3.18. HPN-424
      • 6.3.18.1. Global Antibody Fragments Market, HPN-424, 2018 to 2030 (USD Million)
    • 6.3.19. MGD007
      • 6.3.19.1. Global Antibody Fragments Market, MGD007, 2018 to 2030 (USD Million)
    • 6.3.20. Tebotelimab (MGD013)
      • 6.3.20.1. Global Antibody Fragments Market, Tebotelimab (MGD013), 2018 to 2030 (USD Million)
    • 6.3.21. Bentracimab (PB2452)
      • 6.3.21.1. Global Antibody Fragments Market, Bentracimab (PB2452), 2018 to 2030 (USD Million)
    • 6.3.22. Flotetuzumab (MGD006)
      • 6.3.22.1. Global Antibody Fragments Market, Flotetuzumab (MGD006), 2018 to 2030 (USD Million)
    • 6.3.23. AK104
      • 6.3.23.1. Global Antibody Fragments Market, AK104, 2018 to 2030 (USD Million)
    • 6.3.24. Ozoralizumab
      • 6.3.24.1. Global Antibody Fragments Market, Ozoralizumab, 2018 to 2030 (USD Million)
    • 6.3.25. Sonelokimab (ALX0761)
      • 6.3.25.1. Global Antibody Fragments Market, Sonelokimab (ALX0761), 2018 to 2030 (USD Million)

Chapter 7. Antibody Fragments Market: Segment Analysis, By Application, 2018 - 2030 (USD Million)

  • 7.1. Definitions & Scope
  • 7.2. Global Antibody Fragments Market, By Application, 2018 to 2030 (USD Million)
  • 7.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
    • 7.3.1. Cancer
      • 7.3.1.1. Global Antibody Fragments Market, Cancer, 2018 to 2030 (USD Million)
    • 7.3.2. Immunodeficiency
      • 7.3.2.1. Global Antibody Fragments Market, Immunodeficiency, 2018 to 2030 (USD Million)
    • 7.3.3. Others
      • 7.3.3.1. Global Antibody Fragments Market, Others, 2018 to 2030 (USD Million)

Chapter 8. Antibody Fragments Market: Regional Market Analysis, By Region, 2018 - 2030 (USD Million)

  • 8.1. Definitions & Scope
  • 8.2. Regional market share analysis, 2021&2030
  • 8.3. Regional Market Dashboard
  • 8.4. Regional Market: Key Players
  • 8.5. Market Size, & Forecasts, and Trend Analysis, 2018 to 2030
  • 8.6. North America
    • 8.6.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
    • 8.6.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
    • 8.6.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
    • 8.6.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
    • 8.6.5. U.S.
      • 8.6.5.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
      • 8.6.5.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
      • 8.6.5.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
      • 8.6.5.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
    • 8.6.6. Canada
      • 8.6.6.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
      • 8.6.6.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
      • 8.6.6.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
      • 8.6.6.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
  • 8.7. Europe
    • 8.7.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
    • 8.7.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
    • 8.7.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
    • 8.7.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
    • 8.7.5. Germany
      • 8.7.5.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
      • 8.7.5.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
      • 8.7.5.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
      • 8.7.5.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
    • 8.7.6. U.K.
      • 8.7.6.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
      • 8.7.6.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
      • 8.7.6.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
      • 8.7.6.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
    • 8.7.7. France
      • 8.7.7.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
      • 8.7.7.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
      • 8.7.7.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
      • 8.7.7.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
    • 8.7.8. Italy
      • 8.7.8.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
      • 8.7.8.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
      • 8.7.8.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
      • 8.7.8.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
    • 8.7.9. Spain
      • 8.7.9.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
      • 8.7.9.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
      • 8.7.9.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
      • 8.7.9.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
    • 8.7.10. Russia
      • 8.7.10.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
      • 8.7.10.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
      • 8.7.10.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
      • 8.7.10.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
  • 8.8. Asia Pacific
    • 8.8.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
    • 8.8.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
    • 8.8.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
    • 8.8.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
    • 8.8.5. China
      • 8.8.5.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
      • 8.8.5.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
      • 8.8.5.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
      • 8.8.5.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
    • 8.8.6. Japan
      • 8.8.6.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
      • 8.8.6.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
      • 8.8.6.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
      • 8.8.6.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
    • 8.8.7. India
      • 8.8.7.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
      • 8.8.7.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
      • 8.8.7.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
      • 8.8.7.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
    • 8.8.8. Australia
      • 8.8.8.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
      • 8.8.8.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
      • 8.8.8.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
      • 8.8.8.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
    • 8.8.9. South Korea
      • 8.8.9.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
      • 8.8.9.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
      • 8.8.9.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
      • 8.8.9.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
    • 8.8.10. Singapore
      • 8.8.10.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
      • 8.8.10.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
      • 8.8.10.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
      • 8.8.10.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
  • 8.9. Latin America
    • 8.9.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
    • 8.9.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
    • 8.9.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
    • 8.9.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
    • 8.9.5. Mexico
      • 8.9.5.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
      • 8.9.5.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
      • 8.9.5.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
      • 8.9.5.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
    • 8.9.6. Brazil
      • 8.9.6.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
      • 8.9.6.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
      • 8.9.6.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
      • 8.9.6.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
    • 8.9.7. Argentina
      • 8.9.7.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
      • 8.9.7.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
      • 8.9.7.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
      • 8.9.7.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
  • 8.10. Middle East & Africa
    • 8.10.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
    • 8.10.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
    • 8.10.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
    • 8.10.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
    • 8.10.5. South Africa
      • 8.10.5.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
      • 8.10.5.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
      • 8.10.5.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
      • 8.10.5.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
    • 8.10.6. Saudi Arabia
      • 8.10.6.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
      • 8.10.6.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
      • 8.10.6.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
      • 8.10.6.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
    • 8.10.7. UAE
      • 8.10.7.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
      • 8.10.7.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
      • 8.10.7.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
      • 8.10.7.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Strategy Framework
  • 9.2. Market Participation Categorization
  • 9.3. Company Profile
    • 9.3.1. Pfizer Inc
      • 9.3.1.1. Company Overview
      • 9.3.1.2. Financial Performance
      • 9.3.1.3. Product Benchmarking
      • 9.3.1.4. Strategic Initiatives
    • 9.3.2. Sanofi
      • 9.3.2.1. Company Overview
      • 9.3.2.1.1. Albynx
      • 9.3.2.1.1.1. Company Overview
      • 9.3.2.2. Financial Performance
      • 9.3.2.3. Product Benchmarking
      • 9.3.2.4. Strategic Initiatives
    • 9.3.3. Novartis AG
      • 9.3.3.1. Company Overview
      • 9.3.3.2. Financial Performance
      • 9.3.3.3. Product Benchmarking
      • 9.3.3.4. Strategic Initiatives
    • 9.3.4. Genentech, Inc.
      • 9.3.4.1. Company Overview
      • 9.3.4.2. Financial Performance
      • 9.3.4.3. Product Benchmarking
      • 9.3.4.4. Strategic Initiatives
    • 9.3.5. AbbVie Inc.
      • 9.3.5.1. Company Overview
      • 9.3.5.2. Financial Performance
      • 9.3.5.3. Product Benchmarking
      • 9.3.5.4. Strategic Initiatives
    • 9.3.6. Bristol-Myers Squibb Company
      • 9.3.6.1. Company Overview
      • 9.3.6.2. Financial Performance
      • 9.3.6.3. Product Benchmarking
      • 9.3.6.4. Strategic Initiatives
    • 9.3.7. Johnson & Johnson Services, Inc.
      • 9.3.7.1. Company Overview
      • 9.3.7.2. Financial Performance
      • 9.3.7.3. Product Benchmarking
      • 9.3.7.4. Strategic Initiatives
    • 9.3.8. Lilly
      • 9.3.8.1. Company Overview
      • 9.3.8.2. Financial Performance
      • 9.3.8.3. Product Benchmarking
      • 9.3.8.4. Strategic Initiatives

List of Tables

  • Table 1 Global Antibody Fragments Market, By Region, 2018 - 2030 (USD Million)
  • Table 2 Global Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
  • Table 3 Global Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
  • Table 4 Global Antibody Fragments Market, By Therapy 2018 - 2030 (USD Million)
  • Table 5 Global Antibody Fragments Market, By Application 2018 - 2030 (USD Million)
  • Table 6 North America Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
  • Table 7 North America Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
  • Table 8 North America Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 9 North America Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
  • Table 10 U.S. Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
  • Table 11 U.S. Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
  • Table 12 U.S. Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 13 U.S. Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
  • Table 14 Canada Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
  • Table 15 Canada Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
  • Table 16 Canada Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 17 Canada Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
  • Table 18 Europe Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
  • Table 19 Europe Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
  • Table 20 Europe Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 21 Europe Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
  • Table 22 U.K. Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
  • Table 23 U.K. Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
  • Table 24 U.K. Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 25 U.K. Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
  • Table 26 Germany Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
  • Table 27 Germany Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
  • Table 28 Germany Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 29 Germany Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
  • Table 30 France Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
  • Table 31 France Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
  • Table 32 France Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 33 France Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
  • Table 34 Italy Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
  • Table 35 Italy Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
  • Table 36 Italy Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 37 Italy Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
  • Table 38 Spain Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
  • Table 39 Spain Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
  • Table 40 Spain Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 41 Spain Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
  • Table 42 Russia Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
  • Table 43 Russia Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
  • Table 44 Russia Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 46 Russia Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
  • Table 51 Japan Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
  • Table 52 Japan Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
  • Table 53 Japan Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 54 Japan Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
  • Table 55 China Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
  • Table 56 China Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
  • Table 57 China Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 58 China Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
  • Table 59 India Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
  • Table 60 India Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
  • Table 61 India Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 62 India Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
  • Table 63 Australia Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
  • Table 64 Australia Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
  • Table 65 Australia Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 66 Australia Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
  • Table 67 South Korea Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
  • Table 68 South Korea Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
  • Table 69 South Korea Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 70 South Korea Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
  • Table 71 Singapore Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
  • Table 72 Singapore Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
  • Table 73 Singapore Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 74 Singapore Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
  • Table 75 Latin America Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
  • Table 76 Latin America Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
  • Table 77 Latin America Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 78 Latin America Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
  • Table 79 Brazil Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
  • Table 80 Brazil Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
  • Table 81 Brazil Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 82 Brazil Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
  • Table 83 Mexico Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
  • Table 84 Mexico Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
  • Table 85 Mexico Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 86 Mexico Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
  • Table 87 Argentina Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
  • Table 88 Argentina Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
  • Table 89 Argentina Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 90 Argentina Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
  • Table 91 Middle East & Africa Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
  • Table 92 Middle East & Africa Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
  • Table 93 Middle East & Africa Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 94 Middle East & Africa Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
  • Table 95 South Africa Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
  • Table 96 South Africa Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
  • Table 97 South Africa Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 98 South Africa Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
  • Table 99 Saudi Arabia Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
  • Table 100 Saudi Arabia Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
  • Table 101 Saudi Arabia Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 102 Saudi Arabia Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
  • Table 103 UAE Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
  • Table 104 UAE Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
  • Table 105 UAE Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 106 UAE Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 Market formulation & validation
  • Fig. 7 Antibody fragments market segmentation
  • Fig. 8 Market driver relevance analysis (Current & future impact)
  • Fig. 9 Market restraint relevance analysis (Current & future impact)
  • Fig. 10 Market challenge relevance analysis (Current & future impact)
  • Fig. 11 Penetration & growth prospect mapping
  • Fig. 12 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 13 Porter's Five Forces analysis
  • Fig. 14 Market penetration vs growth prospect mapping
  • Fig. 15 Antibody fragments market: Specificity outlook and key takeaways
  • Fig. 16 Antibody fragments market: Specificity movement analysis
  • Fig. 17 Monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 18 Polyclonal antibodies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Antibody fragments market: Type outlook and key takeaways
  • Fig. 20 Antibody fragments market: Type movement analysis
  • Fig. 21 FAB market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 scFv market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 sdAb market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Antibody fragments market: Therapy outlook and key takeaways
  • Fig. 26 Antibody fragments market: Therapy movement analysis
  • Fig. 27 Monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 PAB market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Pipeline market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Antibody fragments market: Application outlook and key takeaways
  • Fig. 31 Antibody fragments market: Application movement analysis
  • Fig. 32 Cancer market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Immunodeficiency market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Regional marketplace: Key takeaways
  • Fig. 36 Regional outlook, 2021 & 2030
  • Fig. 37 North America antibody fragments market, 2018 - 2030 (USD Million)
  • Fig. 38 U.S. antibody fragments market, 2018 - 2030 (USD Million)
  • Fig. 39 Canada antibody fragments market, 2018 - 2030 (USD Million)
  • Fig. 40 Europe antibody fragments market, 2018 - 2030 (USD Million)
  • Fig. 41 U.K. antibody fragments market, 2018 - 2030 (USD Million)
  • Fig. 42 Germany antibody fragments market, 2018 - 2030 (USD Million)
  • Fig. 43 Italy antibody fragments market, 2018 - 2030 (USD Million)
  • Fig. 44 Spain antibody fragments market, 2018 - 2030 (USD Million)
  • Fig. 45 France antibody fragments market, 2018 - 2030 (USD Million)
  • Fig. 46 Russia antibody fragments market, 2018 - 2030 (USD Million)
  • Fig. 47 Asia Pacific antibody fragments market, 2018 - 2030 (USD Million)
  • Fig. 48 Japan antibody fragments market, 2018 - 2030 (USD Million)
  • Fig. 49 China antibody fragments market, 2018 - 2030 (USD Million)
  • Fig. 50 India antibody fragments market, 2018 - 2030 (USD Million)
  • Fig. 51 Australia antibody fragments market, 2018 - 2030 (USD Million)
  • Fig. 52 South Korea antibody fragments market, 2018 - 2030 (USD Million)
  • Fig. 53 Singapore antibody fragments market, 2018 - 2030 (USD Million)
  • Fig. 54 Latin America antibody fragments market, 2018 - 2030 (USD Million)
  • Fig. 55 Brazil antibody fragments market, 2018 - 2030 (USD Million)
  • Fig. 56 Mexico antibody fragments market, 2018 - 2030 (USD Million)
  • Fig. 57 Argentina antibody fragments market, 2018 - 2030 (USD Million)
  • Fig. 58 MEA antibody fragments market, 2018 - 2030 (USD Million)
  • Fig. 59 South Africa antibody fragments market, 2018 - 2030 (USD Million)
  • Fig. 60 Saudi Arabia antibody fragments market, 2018 - 2030 (USD Million)
  • Fig. 61 UAE antibody fragments market, 2018 - 2030 (USD Million)